A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 14, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions

LymphomasB-cell Lymphomas

Interventions

DRUG

JV-213

Given by (IV) vein

PROCEDURE

Leukapheresis

Given by IV (vein)

Trial Locations (1)

RECRUITING

The University of Texas M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER